Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 401–500 of 1,004
Lipoprotein(a): Genotype–Phenotype Relationship and Impact on Atherogenic Risk
Enkhmaa, B., Anuurad, E., Zhang, W., Tran, T. P., & Berglund, L. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0026 · Cited by 52
“In particular, populations of African descent, including African Americans, have higher Lp(a) levels compared to most other ethnic groups for a range of apo(a) allele sizes.13,14 Due to the extensive apo(a) gene size polymorphism, homozygotes for apo(a) size are rare; a heterozygosity index of approximately 94% was re…”
BackgroundResultInfluentialKotani, K., Șerban, M.-C., Penson, P. E., Lippi, G., & Banach, M. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1188055 · Cited by 55
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Kalra, D. K., Vijayaraghavan, K., Sikand, G., Desai, N. R., Joshi, P. H., Mehta, A., Karmally, W., Vani, A. K., Sitafalwalla, S. J., Puri, R., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.03.007 · Cited by 50
Lipoprotein(a): Emerging insights and therapeutics
Kaur, G., Abdelrahman, K., Berman, A. N., Biery, D. W., Shiyovich, A., Huck, D. M., Garshick, M. S., Blankstein, R., & Weber, B. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100641 · Cited by 53
“The proposed causal role of Lp(a) in coronary artery disease was later corroborated by several other genetic studies and large observational epidemiological studies demonstrating strong continuous association between Lp(a) and ASCVD [15 – 20].”
ResultMusunuru, K., Hickey, K. T., Al‐Khatib, S. M., Delles, C., Fornage, M., Fox, C. S., Frazier, L. Q., Gelb, B. D., Herrington, D. M., Lanfear, D. E., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/hcg.0000000000000020 · Cited by 57
Gómez, M. C. G., Bianchi, M. L., de la Fuente, D., Badimón, L., Padró, T., Corbella, E., & Pintó, X. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.304 · Cited by 50
Tolbus, A., Mortensen, M. B., Nielsen, S. F., Kamstrup, P. R., Bojesen, S. E., & Nordestgaard, B. G. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.277103 · Cited by 50
Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study
Kubota, Y., Folsom, A. R., Ballantyne, C. M., & Tang, W. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.017 · Cited by 50
Antisense Oligonucleotides Targeting Lipoprotein(a)
Langsted, A., & Nordestgaard, B. G. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0792-8 · Cited by 53
Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population
Lim, E. T., Würtz, P., Havulinna, A. S., Palta, P., Tukiainen, T., Rehnström, K., Esko, T., Mägi, R., Inouye, M., Lappalainen, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004494 · Cited by 49
“We adjusted the association for the composite LPA variant with a previously published risk variant (rs3798220) [22], but observed a similarly protective effect (N = 18,270, HR = 0.”
BackgroundMethodSelf-citationLamon-Fava, S., Diffenderfer, M. R., & Marcovina, S. M. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000070 · Cited by 48
“Other sequences in the apo(a) locus also control plasma Lp(a) levels [13], but it is not known if the regulation occurs transcriptionally or post-transcriptionally.”
BackgroundRonald, J., Rajagopalan, R., Cerrato, F., Nord, A. S., Hatsukami, T., Kohler, T., Marcovina, S., Heagerty, P., & Jarvik, G. P. (2011) · Stroke · doi:10.1161/strokeaha.110.591230 · Cited by 47
Lipid control in patients with diabetes mellitus
Betteridge, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.23 · Cited by 58
“The potential importance of lipoprotein(a) as a risk factor for CVD has been re-emphasized following the results of the Precocious Coronary Artery Disease (PROCARDIS) study”
BackgroundEllis, K. L., Pang, J., Chieng, D., Bell, D. A., Burnett, J. R., Schultz, C. J., Hillis, G. S., & Watts, G. F. (2018) · Clinical Cardiology · doi:10.1002/clc.22880 · Cited by 49
Mendelian Randomization: Principles and its usage in Lp(a) research
Lamina, C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.013 · Cited by 52
Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study
Li, J., Lange, L. A., Sabourin, J., Duan, Q., Valdar, W. S. J., Willis, M. S., Li, Y., Wilson, J. G., & Lange, E. M. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.107 · Cited by 49
Niacin: The Evidence, Clinical Use, and Future Directions
Villines, T. C., Kim, A. S., Gore, R. S., & Taylor, A. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0212-1 · Cited by 55
Lewis, J. P., Voora, D., & Beitelshees, A. L. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52900 · Cited by 48
“A rare variant in LPA (rs3798220) was associated with higher concentrations of Lp(a), 82 and carriers had a more than twofold reduction in the risk for cardiovascular disease with aspirin, whereas non-carriers ( .”
Cholesterol crystals in the pathogenesis of atherosclerosis
Baumer, Y., Irei, J. S., & Boisvert, W. A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01100-3 · Cited by 55
Candidate Gene Association Study of Coronary Artery Calcification in Chronic Kidney Disease
Ferguson, J. F., Matthews, G. J., Townsend, R. R., Raj, D. S., Kanetsky, P. A., Budoff, M. J., Fischer, M. J., Rosas, S. E., Kanthety, R., Rahman, M., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.103 · Cited by 53
“Rare variants in LPA (rs3798220) (3,28) and PCSK9 (rs11591147/R46L) (29) are associated with CHD risk.”
Zannad, F., De Backer, G., Graham, I., Lorenz, M., Mancia, G., Morrow, D. A., Reiner, Ž., Koenig, W., Dallongeville, J., Macfadyen, R. J., et al. (2012) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.01023.x · Cited by 46
Arsenault, B. J., Barter, P. J., DeMicco, D. A., Bao, W., Preston, G. M., LaRosa, J. C., Grundy, S. M., DEEDWANIA, P. C., Greten, H., WENGER, N. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114519 · Cited by 48
“The positive association between plasma Lp(a) levels and the risk of events observed in the present study is supported by a significant amount of reports suggesting a role for both Lp(a) levels and LPA genotyped in predicting cardiovascular risk [26, 27].”
BackgroundKrychtiuk, K. A., Kastl, S., Hofbauer, S. L., Wonnerth, A., Goliasch, G., Ozsvár-Kozma, M., Katsaros, K. M., Maurer, G., Huber, K., Dostal, E., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.005 · Cited by 54
Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations
Elbers, C. C., Guo, Y., Tragante, V., van Iperen, E. P. A., Lanktree, M. B., Castillo, B. A., Chen, F., Yanek, L. R., Wojczynski, M. K., Li, Y. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050198 · Cited by 46
“The IBC array has been successfully used for multiple cardiovascular-related phenotypes [9,10,11,12].”
MethodPuri, R., Ballantyne, C. M., Hoogeveen, R. C., Shao, M., Barter, P. J., Libby, P., Chapman, M. J., Erbel, R. M., Arsenault, B. J., Raichlen, J. S., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.026 · Cited by 51
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 55
Thompson, G. R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833e13fd · Cited by 49
Becker, R. C., Voora, D., & Shah, S. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00052-5 · Cited by 48
Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes
Kelsey, M. D., Mulder, H. S., Chiswell, K., Lampron, Z. M., Nilles, E. K., Kulinski, J. P., Joshi, P. H., Jones, W. S., Chamberlain, A. M., Leucker, T. M., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100478 · Cited by 50
FGF19 Signaling Cascade Suppresses APOA Gene Expression
Chennamsetty, I., Claudel, T., Kostner, K., Trauner, M., & Kostner, G. M. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.243055 · Cited by 48
Suwa, S., Ogita, M., Miyauchi, K., Sonoda, T., Konishi, H., Tsuboi, S., Wada, H., Naito, R., Dohi, T., Kasai, T., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.38794 · Cited by 47
Dietary natural products as emerging lipoprotein(a)‐lowering agents
Momtazi‐Borojeni, A. A., Katsiki, N., Pirro, M., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28134 · Cited by 49
“Single nucleotide polymorphisms (SNPs) in the LPA gene are strongly associated with plasma Lp(a) levels (Clarke et al., 2009; Helgadottir et al., 2012; Kamstrup, Tybjærg‐Hansen, Steffensen, & Nordestgaard, 2009).”
BackgroundInfluentialReibis, R. K., Treszl, Wegscheider, Bestehorn, K. P., Karmann, & Voeller, H. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33305 · Cited by 54
“Additionally, more recently a genetic background for the prognostic implication of Lp(a) independent of LDL-C has been described.(33) The increased awareness of accompanying risk factors in younger patients might explain the higher rate of Lp(a) measurements in group 1 during cardiac rehabilitation; however, the Lp(a)…”
Diederiks, N. M., van der Burgt, Y. E. M., Ruhaak, L. R., & Cobbaert, C. M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2199353 · Cited by 45
“Starting in the early 2000s, evidence for a strong causal association between Lp(a) levels and the risk of developing CVD was reestablished, specifically with MI and aortic valve stenosis [14–17].”
BackgroundDumitrescu, L., Glenn, K., Brown-Gentry, K., Shephard, C., Wong, M., Rieder, M. J., Smith, J. D., Nickerson, D. A., & Crawford, D. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016604 · Cited by 46
“Two of the six associated SNPs (rs1321195 and rs7765803) have previously been associated with Lp(a) in a cohort of Europeans[22].”
BackgroundInfluentialPatel, R. S., Sun, Y. V., Hartiala, J., Veledar, E., Su, S., Sher, S., Liu, Y. X., Rahman, A. M., Patel, R., Rab, S. T., et al. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.960229 · Cited by 50
“The LPA locus was not included for logistical reasons despite publication in 2009.(24,25) Genotyping for Emory Cardiovascular BioBank samples was performed using the Centaurus (Nanogen) platform at deCODE genetics, Reykjavik, Iceland, or with the SNPstream (Beckman Coulter) platform at Emory University, Atlanta, Ga.”
MethodVerbeek, R., Boekholdt, S. M., Stoekenbroek, R. M., Hovingh, G. K., Witztum, J. L., Wareham, N. J., Sandhu, M. S., Khaw, K.-T., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066258 · Cited by 43
Yeang, C., Cotter, B. R., & Tsimikas, S. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6634-1 · Cited by 47
Muramatsu, Y., Minami, Y., Kato, A., Katsura, A., Sato, T., Kakizaki, R., Nemoto, T., Hashimoto, T., Fujiyoshi, K., Meguro, K., et al. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100382 · Cited by 46
Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women
Gregersen, I., Høibraaten, E., Holven, K. B., Løvdahl, L., Ueland, T., Mowinckel, M., Dahl, T. B., Aukrust, P., Halvorsen, B. L., & Sandset, P. M. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.10.005 · Cited by 47
Konishi, K., Miyake, T., Furukawa, S., Senba, H., Kanzaki, S., Nakaguchi, H., Yukimoto, A., Nakamura, Y., Watanabe, T., Koizumi, Y., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.026 · Cited by 46
Danik, J. S., Buring, J. E., Chasman, D. I., Zee, R. Y. L., Ridker, P. M., & Glynn, R. J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12056 · Cited by 46
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
“Increased plasma levels of Lp(a), as well as its genetic determinants, have been strongly associated with an increased risk of CAD in large-scale studies 169–172 .”
Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study
Rao, F., Schork, A. J., Maihofer, A. X., Nievergelt, C. M., Marcovina, S. M., Miller, E. R., Witztum, J. L., O’Connor, D. T., & Tsimikas, S. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305306 · Cited by 48
“It is now well accepted that Lp(a) is a highly heritable(22,23) and likely causal risk factor for CVD, particularly with the recent strong supporting data from epidemiological, genome-wide association, and Mendelian randomization studies demonstrating its independent predictive role in CVD, myocardial infarction, and…”
BackgroundSouth Asian Cardiovascular Disease & Cancer Risk: Genetics & Pathophysiology
Palaniappan, L. P., Garg, A., Enas, E. A., Lewis, H., Bari, S., Gulati, M., Flores, C., Mathur, A. K., Molina, C. R., Narula, J., et al. (2018) · Journal of Community Health · doi:10.1007/s10900-018-0527-8 · Cited by 50
“Mendelian randomization and other genetic studies have demonstrated a causal role of blood levels of Lp(a) in CAD [60, 161].”
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
Cui, F., Fang, F., He, Y., Cai, D.-P., He, J. L., & Yang, X. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.06.004 · Cited by 44
Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113499 · Cited by 45
“The variants of LPA have been shown to confer a significant increase in the risk for CHD [33,34]; the large artery atherosclerosis, PAD, and abdominal aortic aneurysm subtypes of ischemic stroke [42]; aortic valve calcification [46]; and aortic valve stenosis [47].”
BackgroundMethodCells and extracellular matrix interplay in cardiac valve disease: because age matters
Spadaccio, C., Mozetic, P., Nappi, F., Nenna, A., Sutherland, F. W. H., Trombetta, M., Chello, M., & Rainer, A. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0534-9 · Cited by 44
Enkhmaa, B., & Berglund, L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811297-7.00013-5 · Cited by 44
Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease
Liu, H., Cao, Y., Jin, J., Zhang, H., Hua, Q., Li, Y., Guo, Y., Zhu, C., Wu, N., Gao, Y., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-316586 · Cited by 45
Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort
Sung, K.-C., Wild, S. H., & Byrne, C. D. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.02.009 · Cited by 45
“Genetic studies show that apo(a) variants are strongly associated with both an increased level of Lp(a) and an increased risk of coronary disease [6,7]; and analyses of large scale prospective studies [8,9] and meta-analysis data [10], show that increased Lp(a) concentrations are a risk factor for CVD.”
ResultVerweij, S. L., de Ronde, M. W. J., Verbeek, R., Boekholdt, S. M., Planken, R. N., Stroes, E. S. G., & Pinto‐Sietsma, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.007 · Cited by 44
Metabolic Syndrome After HIV Acquisition in South African Women
Sobieszczyk, M. E., Werner, L., Mlisana, K. P., Naicker, N., Feinstein, A., Gray, C. M., Masson, L., Passmore, J.-A. S., Williamson, C. E., Karim, Q. A., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001123 · Cited by 44
Littmann, K., Wodaje, T., Alvarsson, M., Bottai, M., Eriksson, M., Parini, P., & Brinck, J. W. (2019) · Diabetes Care · doi:10.2337/dc19-1398 · Cited by 43
“shown to correlate with CVD in different types of studies, including genome-wide association and Mendelian randomization (8,9), population-based cohorts (10), and in a large meta-analysis (11).”
BackgroundLipoprotein (a) and aortic valve calcium in South Asians compared to other race/ethnic groups
Makshood, M., Joshi, P. H., Kanaya, A. M., Ayers, C. R., Budoff, M. J., Tsai, M. Y., Blaha, M. J., Michos, E. D., & Post, W. S. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.010 · Cited by 44
Virani, S. S., Koschinsky, M. L., Maher, L. V., Mehta, A., Orringer, C. E., Santos, R. D., Shapiro, M. D., & Saseen, J. J. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.01.002 · Cited by 46
“The relationship between Lp(a) andASCVD risk has beenwell established in epidemiological studies and meta-analyses, Mendelian randomization studies,(30,31) and genome-wide association studies.(15,32) TheUKBiobankhas demonstrated substantial racial diversity in relation tomedian Lp(a) concentrations.”
BackgroundBerthold, H. K., Laudes, M., Krone, W., & Gouni‐Berthold, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024719 · Cited by 44
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
Hopewell, J. C., Seedorf, U., Farrall, M., Parish, S., Kyriakou, T., Goel, A., Hamsten, A., Collins, R., Watkins, H. C., & Clarke, R. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12187 · Cited by 48
Self-citationSabater‐Lleal, M., Martínez-Pérez, Á., Buil, A., Folkersen, L., Souto, J. C., Bruzelius, M., Borrell, M., Odeberg, J., Silveira, A. M. V., Eriksson, P. O., et al. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.248492 · Cited by 43
“Replication was performed in population-based, unrelated Swedish individuals, 340 men and 322 women with a similar age distribution (33–80 years), who had been recruited at random from the greater Stockholm area for inclusion as control subjects in the Precocious Coronary Artery Disease (PROCARDIS) study (cohort acron…”
MethodInfluentialSelf-citationVavuranakis, M., Jones, S. R., Ziogos, E., Blaha, M. J., Williams, M. S., Foran, P., Schindler, T. H., Lai, S., Schulman, S. P., Gerstenblith, G., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.01.058 · Cited by 43
Thau, H., Neuber, S., Emmert, M. Y., & Nazari‐Shafti, T. Z. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00353-w · Cited by 45
“In addition to apo(a) isoform size, studies indicate other genetic variants that regulate Lp(a) serum levels [12], such as single-nucleotide polymorphisms rs10455872 or rs3798220 [128].”
BackgroundQin, T., Ma, T., Huang, K., Lu, S., Zhong, J., & Li, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01215-5 · Cited by 44
Xie, S., Galimberti, F., Olmastroni, E., Carugo, S., Catapano, A. L., & Casula, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120420 · Cited by 43
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.276931 · Cited by 42
Chieng, D., Pang, J., Ellis, K. L., Hillis, G. S., Watts, G. F., & Schultz, C. J. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.090 · Cited by 42
Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies
Santos, H. O., KONES, R. J., Rumana, U., Earnest, C. P., Izidoro, L. F. M., & Macedo, R. C. O. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.002 · Cited by 43
Pechlivanis, S., Mahabadi, A. A., Hoffmann, P., Nöthen, M. M., Broecker‐Preuss, M., Erbel, R., Moebus, S., Stang, A., & Jöckel, K. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01003-3 · Cited by 43
Maio, S. D., Grüneis, R., Streiter, G., Lamina, C., Maglione, M., Schönherr, S., Öfner, D., Thorand, B., Peters, A., Eckardt, K., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00771-0 · Cited by 45
The Genome-Wide Association Study—A New Era for Common Polygenic Disorders
Roberts, R., Wells, G. A., Stewart, A. F. R., Dandona, S., & Chen, L. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9178-6 · Cited by 50
“A subsequent study has confirmed this finding but, moreover, identified a variant with a more profound effect on the level of circulating lipoprotein a (lp(a)) and a more robust association with CAD [ 60 ].”
ResultLipoprotein(a) and risk of myocardial infarction – genetic epidemiologic evidence of causality
Kamstrup, P. R., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2011) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2010.550311 · Cited by 42
Therapeutic Potential of Lipoprotein(a) Inhibitors
Nicholls, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02046-z · Cited by 45
Emerging Genomic Applications in Coronary Artery Disease
Damani, S. B., & Topol, E. J. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.12.016 · Cited by 43
“In the third and final related study, investigators used a novel cardiac gene chip and assayed for 48,742 common and rare SNPs from several candidate genes in over 7,000 CAD cases and controls (17).”
BackgroundMethodInfluentialPro-Inflammatory Genetic Markers of Atherosclerosis
Incalcaterra, E., Accardi, G., Balistreri, C. R., Caimi, G., Candore, G., Caruso, M., & Caruso, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0329-5 · Cited by 44
Wang, L., Chen, J., Zeng, Y., Wei, J., Jing, J., Li, G., Su, L., Tang, X., Wu, S., & Zhou, L. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307311 · Cited by 41
“Increasing evidence has shown that high Lp(a) levels and single nucleotide polymorphisms (SNPs) in the SLC22A3LPAL2-LPA gene cluster are associated with several risk factors that substantially increase the risk of coronary disease, aortic valve stenosis, and stroke.11,13–15 A large-scale genomewide analysis involving…”
InfluentialCardiovascular and Cancer Risk: The Role of Cardio-oncology
Coviello, J. S. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.2.3 · Cited by 46
“Studies suggest that Lp(a) is a strong, independent predictor of CVD (Bennet et al., 2009; Clarke et al., 2009; The Emerging Risk Factors Collaboration, 2009).”
BackgroundCalcification of the heart: mechanisms and therapeutic avenues
Shekar, C., & Budoff, M. J. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1484282 · Cited by 42
Brandt, E. J., Mani, A., Spatz, E. S., Desai, N. R., & Nasir, K. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.06.010 · Cited by 42
Genomic Variant in IL-37 Confers A Significant Risk of Coronary Artery Disease
Yin, D., Naji, D. H., Xia, Y., Li, S., Bai, Y., Jiang, G., Zhao, Y., Wang, X., Huang, Y., Chen, S., et al. (2017) · Scientific Reports · doi:10.1038/srep42175 · Cited by 41
Man, S., Zu, Y., Yang, X., Deng, Y., Shen, D., Ma, Y., Fu, J., Du, J., Yu, C., Lyu, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.032 · Cited by 42
Genetic insights into cardiometabolic risk factors.
Whitfield, J. B. (2014) · Europe PMC (PubMed Central) · Cited by 53
Update on Abdominal Aortic Aneurysm Research: From Clinical to Genetic Studies
Kuivaniemi, H., Ryer, E. J., Elmore, J. R., Hinterseher, I., Smelser, D. T., & Tromp, G. (2014) · Scientifica · doi:10.1155/2014/564734 · Cited by 40
“Our interest in LPA stemmed from the work by others [58] who demonstrated an association between the alleles of two SNPs in the LPA gene, rs10455872 and rs3798220, and high plasma levels of LPA as well as CAD.”
ResultBerk, K. A., Yahya, R., Verhoeven, A. J. M., Touw, J., Leijten, F. P. J., van Rossum, E. F. C., Wester, V. L., Lips, M. A., Pijl, H., Timman, R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4246-y · Cited by 41
“High Lp(a) levels have consistently been associated with an increased risk of coronary heart disease [6, 9], and results from genetic studies indicate a causal association between high Lp(a) levels and CVD [17, 33, 34].”
BackgroundHippe, D. S., Phan, B. A. P., Sun, J., Isquith, D. A., O’Brien, K. D., Crouse, J. R., Anderson, T. J., Huston, J., Marcovina, S. M., Hatsukami, T. S., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310368 · Cited by 41
Identifying cross-disease components of genetic risk across hospital data in the UK Biobank
Cortés, A., Albers, P. K., Dendrou, C. A., Fugger, L. H., & McVean, G. (2019) · Nature Genetics · doi:10.1038/s41588-019-0550-4 · Cited by 40
Lali, R., Chong, M., Omidi, A., Mohammadi‐Shemirani, P., Le, A., Cui, E., & Paré, G. (2021) · Nature Communications · doi:10.1038/s41467-021-26114-0 · Cited by 43
Moriarty, P. M., & Hemphill, L. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.003 · Cited by 40
“However, the latest data reveal an increased atherogenicity and risk of CVD associated with Lp(a) regardless of LDL-C levels.(42,43) In 2010 the German government approved LA treatments for patients with ongoing CAD and Lp(a) levels greater than 60 mg/dL (Normal<30 mg/dL), irrespective of LDL-C levels.”
BackgroundSaid, M. A., Yeung, M. W., van de Vegte, Y. J., Benjamins, J. W., Dullaart, R. P. F., Ruotsalainen, S., Ripatti, S., Natarajan, P., Juarez-Orozco, L. E., Verweij, N., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315300 · Cited by 39
“SNPs were considered valid instrumental variables for the MR analyses if (1) they were strongly associated with the risk factor of interest, (2) the SNPs were not associated with confounders of the association between risk factor and outcome, and (3) the SNPs affected the outcome exclusively through their effect on th…”
MethodGlobal Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease
Barkas, F., Brandts, J., Bacquer, D. D., Jennings, C. S., Backer, G. D., Kotseva, K., Rydén, L., Lip, G. Y. H., Santos, R. D., Libby, P., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.010 · Cited by 39
Orho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 35
Yang, X., Sethi, A. A., Yanek, L. R., Knapper, C., Nordestgaard, B. G., Tybjærg‐Hansen, A., Becker, D. M., Mathias, R. A., Remaley, A. T., & Becker, L. C. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001402 · Cited by 42
“A large Mendelian randomization study demonstrated that a genetically determined doubling of Lp(a) was associated with a 22% increase in risk.(47) Additional studies may determine whether variants in SCARB1 have an impact on atherosclerosis.”
Ljungberg, J., Holmgren, A., Bergdahl, I. A., Hultdin, J., Norberg, M., Näslund, U., Johansson, B. H., & Söderberg, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007160 · Cited by 40
Lipids in South Asians: Epidemiology and Management
Makshood, M., Post, W. S., & Kanaya, A. M. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0618-9 · Cited by 42
Wu, M., Xu, K., Guo, Y., Yu, J., Wu, Y., & Lin, L. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06906-9 · Cited by 40
Raygor, V., & Khera, A. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01331-z · Cited by 39
Sohn, W. Y., Winkle, P. J., Neutel, J., Wu, Y., Jabari, F., Terrio, C., Varrieur, T., Wang, J., & Hellawell, J. L. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.07.008 · Cited by 39
Doerfler, A. M., Park, S. H., Assini, J. M., Youssef, A., Saxena, L., Yaseen, A. B., Giorgi, M. D., Chuecos, M. A., Hurley, A. E., Li, A., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.009 · Cited by 39
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0360-6 · Cited by 42
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.